EP 2077842 A2 20090715 - USE OF AN EGFR ANTAGONIST FOR THE TREATMENT OF GLOMEROLONEPHRITIS
Title (en)
USE OF AN EGFR ANTAGONIST FOR THE TREATMENT OF GLOMEROLONEPHRITIS
Title (de)
VERWENDUNG EINES EGFR-ANTAGONISTEN ZUR BEHANDLUNG VON GLOMEROLONEPHRITIS
Title (fr)
UTILISATION D'UN ANTAGONISTE DU RÉCEPTEUR EGFR POUR LE TRAITEMENT DE LA GLOMÉRULONÉPHRITE
Publication
Application
Priority
IB 2006003915 W 20061031
Abstract (en)
[origin: WO2008053270A2] The present invention relates to uses, methods and compositions for treating immune-mediated glomerulonephritis, such as crescentic glomerulonephritis. More specifically, the invention relates to the use of an EFGR antagonist or of an inhibitor of EGFR or HB-EGF expression for the treatment of said diseases.
IPC 8 full level
A61K 31/47 (2006.01); A61K 31/517 (2006.01); A61K 31/519 (2006.01); A61K 31/5377 (2006.01); A61P 13/12 (2006.01)
CPC (source: EP US)
A61K 31/47 (2013.01 - EP US); A61K 31/517 (2013.01 - EP US); A61K 31/519 (2013.01 - EP US); A61K 31/5377 (2013.01 - EP US); A61P 13/12 (2017.12 - EP)
Citation (search report)
See references of WO 2008053270A2
Citation (examination)
- WO 2008018881 A1 20080214 - OSI PHARM INC [US], et al
- WO 0134574 A1 20010517 - OSI PHARM INC [US]
- MERCK: "The Merck Manual", 1 January 1999, MERCK
Designated contracting state (EPC)
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR
DOCDB simple family (publication)
WO 2008053270 A2 20080508; WO 2008053270 A3 20080626; EP 2077842 A2 20090715; US 2010104558 A1 20100429; US 8198266 B2 20120612
DOCDB simple family (application)
IB 2006003915 W 20061031; EP 06842351 A 20061031; US 44749809 A 20091204